Manifold Bio Announces Strategic Collaboration with Roche to Develop Multiple Next-Generation Brain Shuttles for Neurological Diseases

Core Insights - Manifold Bio has announced a strategic research collaboration and license agreement with Roche to enhance drug discovery for neurological and neurodegenerative diseases [1] Company Overview - Manifold Bio is a platform therapeutics company that specializes in AI-guided drug discovery and direct-to-vivo measurement [1] - The company utilizes a proprietary tissue-targeting shuttle portfolio and an AI-driven in vivo discovery engine called mDesign [1] Partnership Details - The collaboration with Roche aims to develop multiple next-generation blood-brain barrier (BBB) shuttles [1] - This partnership is focused on creating innovative treatments for neurological and neurodegenerative disorders [1]